Faculty

David J. Sas, D.O.

Clinical Studies

24-Hydroxylase Deficiency and CYP24A1 Mutation Patient Registry Rochester, Minn.
You are being asked to take part in this research registry because you or your family member is suspected to have a 24-hydroxylase deficiency.
Characterization of Monogenic Kidney Stone Diseases Rochester, Minn.
90 genes related to Monogenic Stone Disease will be determined via DNA analysis by the Mayo Rare Kidney Stone Consortium (RKSC) research staff.
Collaborative Research on Children with Kidney Stones: A Registry Rochester, Minn.
The purpose of this study is to establish a database to collect and analyze information on metabolic and environmental risk factors for kidney stone formation in children.

A Phase 2 Open-Label Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Nedosiran in Pediatric Patients from Birth to 11 Years of Age with Primary Hyperoxaluria and Relatively Intact Renal Function (PHYOX8) Rochester, Minn.
The purpose of this study is to evaluate the safety, effectiveness, and pharmacokinetics (PK, how a drug is metabolized by the body) of Nedosiran in neonates, infants, and young children (birth to 11 years of age) with primary hyperoxaluria (type 1 [PH1] and type 2 [PH2]), and relatively intact renal function based upon eGFR and serum creatinine.
Assessment of Health-related Quality of Life in Rare Kidney Stone Formers in the Rare Kidney Stone Consortium Rochester, Minn.
Assessment of Health-related Quality of Life in Rare Kidney Stone Formers in the Rare Kidney Stone Consortium
ILLUMINATE-B: An Open-Label Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Lumasiran in Infants and Young Children With Primary Hyperoxaluria Type 1 Rochester, Minn. The purpose of the study is to determine if the investigational medicine, lumasiran, is able to reduce the production of oxalate in the liver and to evaluate the safety of lumasiran and how the body responds to it.